Expanded Access to Fosigotifator

Cree Leukoencephalopathy, Vanishing White Matter

Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme, Fosigotifator, FGT, ABBV-CLS-7262, 2025-10780, C25-693, Vanishing White Matter, Cree Leukoencephalopathy

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

No related papers found yet.